ST
TVTX icon

Spot Trading’s Travere Therapeutics TVTX Stock Holding History

Spot Trading’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,785
Closed -$261K – 3321
2016
Q4 		$261K Sell
13,785
-3,456
-20% -$70.7K 0.01% 1781
2016
Q3 		$386K Buy
+17,241
New +$328K 0.01% 1675
2016
Q2 		– Sell
-16,781
Closed -$272K – 3834
2016
Q1 		$229K Buy
+16,781
New +$255K ﹤0.01% 2123

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Spot Trading's TVTX Position: Q1 2017 in Review

Spot Trading sold out of Travere Therapeutics (TVTX) in Q1 2017, closing a stake of 13,785 shares — an estimated $261K sold.

Spot Trading first reported a position in TVTX in Q1 2016 and held it in 3 quarters. The position peaked at $386K in Q3 2016. 114 funds tracked by Wall St. Rank hold TVTX as of Q1 2017.

  • Spot Trading reported no remaining Travere Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Spot Trading sold 13,785 Travere Therapeutics shares in Q1 2017, an estimated $261K.
  • Spot Trading first reported a position in Travere Therapeutics in Q1 2016 and held it in 3 quarters.
  • Spot Trading's Travere Therapeutics position peaked at $386K in Q3 2016.
  • 114 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2017.

Based on Spot Trading's 13F filing for Q1 2017, filed 1 May 2017.